The phase II BATTLE-2 trial focused primarily on KRAS-mutant NSCLC tumors and was conducted with the goal of determining biomarkers for increased the efficacy of targeted treatments and the efficacy of an SSS described in the BATTLE study. This evidence concerns the gene KRAS and non-small cell lung carcinoma.